Pressure Sensitive Adhesive Means Patents (Class 424/448)
  • Patent number: 9926470
    Abstract: A two-phase adhesive composition and selective debonding agent are described. The adhesive composition comprises a substantially continuous first phase comprising a pressure sensitive adhesive and a discontinuous second phase comprising crosslinked silicone gel microparticles. When applied, the selective debonding agent is absorbed by the gel microparticles. The gel microparticles change size or shape and facilitate debonding the adhesive from a substrate by decreasing the contact area between the adhesive and the substrate. Methods to selectively debond pressure sensitive adhesive compositions, methods of making the pressure sensitive adhesive compositions, articles that utilize the pressure sensitive adhesive composition, adhesive systems, and kits that include an article containing the pressure sensitive adhesive composition and the selective debonding agent, are also described.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: March 27, 2018
    Assignee: Avery Dennison Corporation
    Inventor: Neal Carty
  • Patent number: 9919141
    Abstract: A method for manufacturing a needle-shaped body, including supplying a first aqueous solution to an intaglio plate, supplying a second aqueous solution to the intaglio plate, drying the first and second aqueous solutions in the intaglio plate such that a dried body is formed on the intaglio plate, and separating the dried body from the intaglio plate such that a needle-shaped body including a needle-shaped projection and a support base which supports the needle-shaped projection is obtained. The intaglio plate includes a recess corresponding to the needle-shaped projection, the first aqueous solution is supplied to fill at least a portion of the recess, the first aqueous solution and the second aqueous solution are immiscible, the first aqueous solution forms a projection side layer in the needle-shaped body, and the second aqueous solution forms a support base side layer on the projection side layer in the needle-shaped body.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: March 20, 2018
    Assignee: TOPPAN PRINTING CO., LTD.
    Inventors: Hanae Tagami, Hiroyuki Kato
  • Patent number: 9907767
    Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: March 6, 2018
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Patent number: 9889081
    Abstract: The present invention provides methods and compositions for reducing pigmentation.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: February 13, 2018
    Assignees: The Regents of the University of California, Board Of Regents, The University Of Texas System
    Inventors: Anand Ganesan, Michael A. White, Patrick J. Farmer
  • Patent number: 9877948
    Abstract: A method for preparing a transdermal absorption composition includes mixing rotigotine and an antioxidant at a weight ratio of 1:0.0001 to 0.1. A transdermal therapeutic system includes a substrate and a drug-containing adhesive layer disposed on the substrate and including an antioxidant at a weight ratio of 1:0.0001 to 0.1. The method and system of the present invention suppress the crystallization of rotigotine as well as the generation of related substances, thereby increasing the long-term storage stability of a therapeutic product containing rotigotine or related substances.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 30, 2018
    Assignee: SK Chemicals Co., Ltd.
    Inventors: Wonno Youn, Yeo-Jin Park, Hun-Teak Kim
  • Patent number: 9844515
    Abstract: The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: December 19, 2017
    Assignee: Hexal AG
    Inventors: Jens Fleschhut, Susanne Feinaeugle, Karin Lauer
  • Patent number: 9833419
    Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: December 5, 2017
    Assignee: NOVEN PHARMACEUTICALS, INC.
    Inventor: Juan Mantelle
  • Patent number: 9808609
    Abstract: The invention provides a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bloom even when an organic fluid component having high polarity is contained therein. The patch contains a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 500,000-1,600,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: November 7, 2017
    Assignee: Nitto Denko Corporation
    Inventors: Masato Nishimura, Yoshihiro Iwao, Katsuhiro Okada, Kensuke Matsuoka
  • Patent number: 9808416
    Abstract: An oral care composition and methods for making and using same are provided. In at least one embodiment, the oral care composition can include ethylcellulose, a binder, a plasticizer, a fluoride compound, a solvent, and fumed silica. In another embodiment, the oral care composition can include ethylcellulose, hydrogenated rosin, and acetyl tributyl citrate.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: November 7, 2017
    Assignee: Colgate-Palmolive Company
    Inventors: Marian Georges, Andre Michelle Morgan, Sarita Vera Mello, Pierre Lambert, Claude Blanvalet
  • Patent number: 9801950
    Abstract: The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: October 31, 2017
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
  • Patent number: 9803115
    Abstract: Disclosed is an adhesive hydrogel containing a polymer matrix, water, and a polyhydric alcohol, wherein the polymer matrix contains a copolymer of a monofunctional monomer with a single polymerizable C—C double bond and a polyfunctional monomer with two or more polymerizable C—C double bonds, the monofunctional monomer contains a nonionic (meth)acrylamide-based monomer, and the polyfunctional monomer has a composition formula: ClHmOn, where O is an oxygen atom in an ether bond, l is an integer greater than or equal to 4, m is an integer greater than or equal to 6, and n is an integer greater than or equal to 0.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: October 31, 2017
    Assignee: Sekisui Plastics Co., Ltd.
    Inventors: Takaaki Hatori, Kaori Sato, Takahiko Fujita, Kengo Nakamura
  • Patent number: 9789060
    Abstract: The present disclosure relates to a carrier for oromucosal, especially sublingual administration of physiologically active substances, especially of medicinal drugs, which consists of at least one elastic layer (1) of polymer nanofibers workable according to the shape of the selected wall of mouth cavity to which it should be applied and in this elastic layer (1) of polymer nanofibers a drug and/or other physiologically active substance are deposited in a releasable manner.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: October 17, 2017
    Assignee: INSTAR TECHNOLOGIES A.S.
    Inventors: Denisa Stranska, Adela Klabanova, Pavel Dolezal, Petr Vrbata, Pavel Berka, Marie Musilova
  • Patent number: 9789005
    Abstract: An antimicrobial medical dressing provides a combination of antimicrobial agents in various concentrations that protect against microorganisms, absorb exudates, and promote healing. The antimicrobial agents may include compositions of ethanol, hydrogen peroxide, and/or ethylenediaminetetraacetic acid.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: October 17, 2017
    Assignee: Hyprotek, Inc.
    Inventors: Patrick O. Tennican, L. Myles Phipps
  • Patent number: 9782516
    Abstract: A therapeutic formulation is described for a drug delivery balloon comprising a therapeutic formulation which includes a therapeutic agent and an adhesion additive. The adhesion additive promotes adhesion of the therapeutic formulation a vessel wall of a subject. A system and a method of manufacturing a system including an expandable member having a working length with the therapeutic formulation disposed along at least a portion of the working length is also provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 10, 2017
    Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventors: Stephen D. Pacetti, John Stankus
  • Patent number: 9775882
    Abstract: Medical devices and methods including polymers having biologically active agents therein are disclosed. The medical devices can be useful as implantable devices such as orthopedic implants.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: October 3, 2017
    Assignee: Medtronic, Inc.
    Inventors: Phillip Edward McDonald, Christopher M. Hobot
  • Patent number: 9763833
    Abstract: Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: September 19, 2017
    Assignee: Hollister Incorporated
    Inventors: Michael Gerard Taylor, Richard Iwao Murahata
  • Patent number: 9707189
    Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of an acidic drug, comprising a polyvalent alcohol having 3-8 carbon atoms, a higher alcohol having 12-20 carbon atoms and an organic amine having 2-9 carbon atoms.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 18, 2017
    Assignee: NITTO DENKO CORPORATION
    Inventors: Arimichi Okazaki, Tsuyoshi Mukobata, Sachiko Sakamoto, Akinori Hanatani
  • Patent number: 9707187
    Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of a drug, particularly, a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms and a polyvalent alcohol having 3-8 carbon atoms. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms, a polyvalent alcohol having 3-8 carbon atoms and an organic amine having 2-9 carbon atoms.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 18, 2017
    Assignee: NITTO DENKO CORPORATION
    Inventors: Arimichi Okazaki, Tsuyoshi Mukobata, Sachiko Sakamoto, Akinori Hanatani
  • Patent number: 9700552
    Abstract: The invention provides transdermal patches comprising an adhesive and a composition comprising naltrexone and either methyl oleate or isopropyl myristate, a kit comprising a plurality of such transdermal patches, a composition comprising naltrexone and methyl oleate, such a composition for use as a medicament, and compositions comprising naltrexone and methyl oleate or isopropyl myristate for use in the treatment of alcoholism or opiate addiction.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: July 11, 2017
    Assignee: Syntropharma Limited
    Inventor: Ludwig Jan Weimann
  • Patent number: 9669042
    Abstract: Disclosed are compositions and formulations comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and adapted for use in a bath or soak or bath beads, powders, salts, and oils, kits, and methods of treatment using the same. Also disclosed are lozenges, suppositories, patches, and topical creams comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and methods of treatment using the same. In some embodiments the joint conditions include osteoarthritis.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 6, 2017
    Assignee: Vital Medicine, LLC
    Inventors: Anjan Chatterji, Grant Cooper, David Schwartz
  • Patent number: 9669199
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 6, 2017
    Assignee: Chrono Therapeutics Inc.
    Inventors: Guy DiPierro, Steven A. Giannos
  • Patent number: 9549903
    Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin cont
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: January 24, 2017
    Assignee: PURDUE PHARMA L.P.
    Inventors: Thomas Hille, Gabriel Wauer, Kevin John Smith, Helen Elizabeth Johnson, Gillian Elizabeth Mundin
  • Patent number: 9545376
    Abstract: Dissolvable unit dose constructs and their method of manufacture are disclosed in which the unit dose constructs are formed of a composition including a polymer matrix that includes a water soluble polymer, active ingredient, and a liquid carrier. The composition is deposited directly, such as by stenciling, to form individual unit doses without the need to cut and convert long, continuous rolls of film.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: January 17, 2017
    Assignee: ARx, LLC
    Inventors: Matthew K. Musho, John H. Lind, Scott D. Barnhart
  • Patent number: 9533071
    Abstract: A monomeric adhesive composition includes a stabilized polymerizable monomer, such as a 1,1-disubstituted monomer, including a cyanoacrylate, and a wound healing agent, wherein the wound healing agent is 5,5-disubstitutedhydantoin, including phenytoin; and a method for making said composition.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: January 3, 2017
    Assignee: Adhezion Biomedical, LLC
    Inventors: Sheng Zhang, Rafael Ruiz, Sr.
  • Patent number: 9517211
    Abstract: A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: December 13, 2016
    Assignee: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Kunihiko Matsushita, Mamoru Naruse, Kenichi Hattori
  • Patent number: 9504825
    Abstract: A percutaneous penetration enhancing apparatus includes a sheet member capable of being placed on a skin; a plurality of skin condition sensors arranged on the sheet member, each of the plurality of skin condition sensors detecting information related to a condition of the skin; and a plurality of percutaneous penetration enhancing elements arranged on the sheet member, each of the plurality of percutaneous penetration enhancing elements being operated on the basis of the information detected by one or more of the plurality of skin condition sensors.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: November 29, 2016
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Kaori Ajiki, Toshimitsu Minowa
  • Patent number: 9492650
    Abstract: The present invention relates generally to iontophoretic drug delivery systems for transdermal delivery of therapeutic agents and, more particularly, to packaging such systems for long shelf life and easy assembly for use. The system package includes an iontophoretic skin worn patch component that accommodates a power source, electronics, electrodes and a drug pack component that carries a therapeutic agent which is contained as a separate sealed component. The packaged system further provides for ease of assembly at the time of use.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: November 15, 2016
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventor: Todd A. Krinke
  • Patent number: 9492401
    Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.
    Type: Grant
    Filed: December 27, 2010
    Date of Patent: November 15, 2016
    Assignee: Mylan Technologies, Inc.
    Inventors: Kristin Jackson, Kenneth James Miller, II
  • Patent number: 9474835
    Abstract: The object of the present invention is achieved by providing a copolymer, in particular, a block copolymer which has excellent coating formation ability, adhesive properties to a substrate, and does not adsorb protein; an antithrombotic coating agent which has superior antithrombotic properties and adhesive properties to a substrate to those of the conventional antithrombotic coating agent; and a medical instrument which is obtained by coating the antithrombotic coating agent, and the block copolymer includes a polymer (A) containing a (meth)acrylic ester monomer and a polymer (B) containing a (meth)acrylamide monomer and has excellent coating formation ability and high adhesive properties to a substrate.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: October 25, 2016
    Assignees: Kawamura Institute of Chemical Research, DIC Corporation
    Inventors: Kazutoshi Haraguchi, Kazuomi Kubota, Tooru Takehisa, Tetsuo Takada, Noriko Santou
  • Patent number: 9422463
    Abstract: Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings, ostomy skin barriers, and ostomy barrier rings incorporating the compositions.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: August 23, 2016
    Assignee: HOLLISTER, INC.
    Inventors: Michael Gerard Taylor, Richard Iwao Murahata
  • Patent number: 9408802
    Abstract: A transdermal formulation and method of treatment includes providing an active pharmaceutical ingredient, a poly-isobutylene or silicone PSA, optionally, an oil, a crosslinked polyvinylpyrrolidone, and optionally, silicon dioxide, wherein said formulation is prepared on a backing in a three layer transdermal delivery system formulated to provide transdermal delivery and therapeutic levels for up to seven days and optionally with an overlay system required to show bioequivalence.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: August 9, 2016
    Assignee: ProSolus, Inc.
    Inventor: Rod L. Hartwig
  • Patent number: 9408809
    Abstract: The invention relates to a method for preventing the crystallization of a pharmaceutical in a polymer film, wherein the solvent-containing coating compound, which comprises a matrix-forming polymer or polymer mixture and at least one pharmaceutical and is spread to produce the polymer film, is temporarily dried at temperatures that is at least 10° C. above the melting temperature of the pharmaceutical contained in the coating compound. The maximum temperature is thus higher than that which is required for mere drying and obviates the need for an additional, time-consuming and expensive work step.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: August 9, 2016
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Johannes Josef Leonhard, Walter Mueller
  • Patent number: 9375422
    Abstract: Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: June 28, 2016
    Assignee: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Mamoru Naruse, Kenichi Hattori, Kunihiko Matsushita
  • Patent number: 9370495
    Abstract: The present invention provides a patch having a backing and a pressure-sensitive adhesive layer on the backing, wherein the pressure-sensitive adhesive layer contains a pressure-sensitive adhesive base composed of a polymer having a hydroxyl group, a drug, polyvinylpyrrolidone and a multivalent metal chloride.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: June 21, 2016
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Arata Toshimitsu, Naoko Fujita
  • Patent number: 9364487
    Abstract: A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains the progestin, the estrogen and an additional anti-oxidant. Methods of improving the stability of progestin-containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti-oxidants in the compositions.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: June 14, 2016
    Assignee: Agile Therapeutics, Inc.
    Inventors: Charles G. Arnold, Agis Kydonieus, Thomas M. Rossi, Alfred F. Altomari
  • Patent number: 9351942
    Abstract: The invention provides a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bloom even when an organic fluid component having high polarity is contained therein. The patch contains a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 1,700,000-6,500,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: May 31, 2016
    Assignee: Nitto Denko Corporation
    Inventors: Masato Nishimura, Yoshihiro Iwao, Katsuhiro Okada, Kensuke Matsuoka
  • Patent number: 9352047
    Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 31, 2016
    Assignee: ABON PHARMACEUTICALS, LLC
    Inventors: Salah U. Ahmed, Yanming Zu, Karunakar Neelam, Saad Muntazim, Tahseen A. Chowdhury, Shiying Tian
  • Patent number: 9327105
    Abstract: The present invention relates to an active transdermal drug delivery system performing transdermal drug delivery comprising of a patch capable of being attachable to the skin of the subject; at least one electrical energy power input; a plurality of converters/energy transducers configured for converting the electrical energy to different forms of energy; and a controller including a programmable microprocessor configured for providing the intensity, sequence, nature, and timing information for the different energies supplied and thereby providing activating signals to the said converters for the transdermal drug delivery by the said patch, and a method for performing transdermal drug delivery using said electronic patch.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 3, 2016
    Assignee: ITRACE BIOMEDICAL INC.
    Inventors: Radhakrishnan Ramdas, Kartik Karri, Chidella Venkata Krishna Mohan Sharma
  • Patent number: 9320742
    Abstract: Described are transdermal drug delivery systems for the transdermal administration of testosterone, comprising a polymer matrix and testosterone. Methods of making and using such systems also are described.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: April 26, 2016
    Assignee: NOVEN PHARMACEUTICALS, INC.
    Inventor: Juan A. Mantelle
  • Patent number: 9308202
    Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: April 12, 2016
    Assignee: PURDUE PHARMA L.P.
    Inventors: Thomas Hille, Michael Horstmann, Walter Mueller
  • Patent number: 9308187
    Abstract: A patch comprising a support layer and an adhesive layer, wherein the adhesive layer comprises diclofenac sodium, dimethyl sulfoxide, and citric acid; a mass ratio between the diclofenac sodium and the citric acid (mass of diclofenac sodium:mass of citric acid) is 1:0.15 to 1:0.45; and a mass ratio between the diclofenac sodium and the dimethyl sulfoxide (mass of diclofenac sodium:mass of dimethyl sulfoxide) is 1:0.75 to 1:3.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 12, 2016
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Eisuke Hatanaka, Yasunori Takada, Takaaki Terahara, Naruhito Higo
  • Patent number: 9306202
    Abstract: A separator for a secondary battery and a secondary battery including the same, the separator including a porous substrate; a patterned fabric layer on at least one side of the porous, the patterned fabric layer having patterns; and a polymer coating layer on the patterned fabric layer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 5, 2016
    Assignee: SAMSUNG SDI CO., LTD.
    Inventor: Chan-Seok Kim
  • Patent number: 9289279
    Abstract: A composite prosthesis and method for limiting the incidence of postoperative adhesions. The composite includes a non-inflammatory or coated mesh and a barrier material which prevents exposure of tissue elsewhere in the body to tissue covered by the composite prosthesis. The barrier material is absorbable which allows tissue through-growth and localization of the composite prosthetic. In use, the composite prosthesis is positioned over the tissue defect and may be positioned with the barrier material oriented against the tissue defect or repair site.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: March 22, 2016
    Assignee: PROMETHEAN SURGICAL DEVICES, LLC
    Inventors: Jeffrey A. Wilson, Michael Milbocker
  • Patent number: 9265752
    Abstract: A Rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in matrix mixture system. The acrylic pressure-sensitive adhesive may be present in an amount of about 1-25% by weight in the matrix mixture system. The silicone pressure-sensitive adhesive may be present in an amount of about 65-98% by weight in the matrix mixture system. The composition further includes 1-40% of Rotigotine on the basis of the total weight of the composition. The composition provides improved properties in the solubility, release and initial penetration level of Rotigotine. Also disclosed is a transdermal patch that includes the Rotigotine-containing composition, as well as methods of manufacturing and using the Rotigotine-containing composition.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: February 23, 2016
    Assignee: Jiangsu Kangbeide Pharmaceuticals Co. Ltd.
    Inventors: Shuming Wang, Huiyong Xue, Li Wang, Enhong Zhang, Hongjun Lian, Xiaoyan Shi, Guohua Chi, Yucheng Lu, Xiquan Liu, Li Song, Xuying Zhong, Hongguang Du
  • Patent number: 9259397
    Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: February 16, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Patent number: 9248104
    Abstract: Transdermal delivery systems for delivery of Alzheimer's pharmaceuticals, particularly donepezil, over one to seven days are disclosed which deliver the free-base form of the Alzheimer's pharmaceutical at a skin permeation rate such that blood levels of the Alzheimer's pharmaceuticals are comparable to the approved oral dosage forms.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: February 2, 2016
    Assignee: Core Tech Solutions, Inc.
    Inventors: Kirti H Valia, Vatsala S Ramaraju
  • Patent number: 9238088
    Abstract: An adhesion inhibiting surgical barrier. The surgical barrier includes a wound-facing polymeric coating comprising an enteric polymer; and at least one flexible substrate, the at least one flexible substrate having at least one exterior surface, wherein the polymeric coating is applied to the at least one flexible substrate to substantially cover the at least one exterior surface thereof. A method of inhibiting the formation of adhesions in a patient who has undergone a surgical procedure and a method of repairing a gastric or duodenal perforation are also described herein.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: January 19, 2016
    Assignee: Ethicon, Inc.
    Inventors: Robert W. Van Holten, Jagdishchandra C. Patel
  • Patent number: 9226902
    Abstract: A solid dispersion transdermal drug delivery system comprising a therapeutic agent in a stable amorphous form and a combination polymeric stabilizing and dispersing agent having a hydrogen bond-forming functional group, and a method of manufacturing these systems is provided. The weight ratio of the combination polymeric stabilizing and dispersing agent to the therapeutic agent is also disclosed.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: January 5, 2016
    Assignee: Mylan Technologies Inc.
    Inventor: Jiashang Tang
  • Patent number: 9204962
    Abstract: Implantable corneal and intraocular implants such as a mask are provided. The mask can improve the vision of a patient, such as by being configured to increase the depth of focus of an eye of a patient. The mask can include an aperture configured to transmit along an optical axis substantially all visible incident light. The mask can further include a transition portion that surrounds at least a portion of the aperture. This portion can be configured to switch from one level of opacity to another level of opacity through the use of a controllably variable absorbance feature such as a switchable photochromic chromophore within a polymer matrix.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 8, 2015
    Assignee: AcuFocus, Inc.
    Inventor: Thomas A. Silvestrini
  • Patent number: 9198876
    Abstract: Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: December 1, 2015
    Assignee: Agile Therapeutics, Inc.
    Inventors: Thomas M. Rossi, Marie Foegh, Agis Kydonieus